Camurus AB
STO:CAMX

Watchlist Manager
Camurus AB Logo
Camurus AB
STO:CAMX
Watchlist
Price: 593 SEK -0.42%
Market Cap: 35.5B SEK

EV/EBIT
Enterprise Value to EBIT

34.7
Current
53.7
Median
16.6
Industry
Lower than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
34.7
=
Enterprise Value
32.2B SEK
/
EBIT
927.2m SEK
All Countries
Close
Market Cap EV/EBIT
SE
Camurus AB
STO:CAMX
35.6B SEK 34.7
US
Eli Lilly and Co
NYSE:LLY
926.9B USD 36.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 17 702.3
US
Johnson & Johnson
NYSE:JNJ
484.7B USD 20.5
CH
Roche Holding AG
SIX:ROG
253.9B CHF 13.4
UK
AstraZeneca PLC
LSE:AZN
211.1B GBP 158.2
CH
Novartis AG
SIX:NOVN
201.5B CHF 14.3
US
Merck & Co Inc
NYSE:MRK
240.5B USD 10.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 10.5
IE
Endo International PLC
LSE:0Y5F
202.5B USD 805.4
US
Pfizer Inc
NYSE:PFE
143.8B USD 10.2
EBIT Growth EV/EBIT to Growth
SE
Camurus AB
STO:CAMX
Average EV/EBIT: 1 710.6
34.7
73%
0.5
US
Eli Lilly and Co
NYSE:LLY
36.3
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.5
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.4
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.2
23%
6.9
CH
Novartis AG
SIX:NOVN
14.3
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.7
8%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
10.5
1%
10.5
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
8%
1.3

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
32.2
2-Years Forward
EV/EBIT
19.1
3-Years Forward
EV/EBIT
13.1